A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
SB-681323 inhibits the action of an enzyme which is known to contribute to the inflammation
seen in such conditions as Chronic Obstructive Pulmonary Disease and Rheumatoid Arthritis.
This study will explore the safety of this drug and its blood levels when given in
intravenous form to healthy human volunteers.